Loading company…
numares develops NMR spectroscopy diagnostic systems and biomarker tests for chronic diseases.
Founded in 2004, numares develops diagnostic tests using nuclear magnetic resonance spectroscopy for chronic kidney, liver and cardiac diseases. Its AXINON® systems measure biomarkers from serum samples and are marketed in the United States and European Union. The company is based in Regensburg, Germany. In December 2022, it raised EUR 20 million in venture debt led by the European Investment Bank.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in